RxDoctor Payments DataLook up a doctor →

Santosh Kesari, MD

Neurology · Santa Monica, CANPI 1891785960

Payments from drug & device makers

$1,574,713in general payments, 2019–2025

Across 526 payments — averaging $2993.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$500K
  • Icad, Inc$257K
  • Bavarian Nordic A/s$145K
  • Boehringer Ingelheim$137K
  • Blue Earth Diagnostics$122K
  • Partner Therapeutics, Inc.$86K
  • plus $328K from 54 others
$47,447in research payments, 2019–2025

Across 6 payments — averaging $7907.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Aurobindo Pharma USA, Inc.$39K
  • Bristol Myers Squibb$4K
  • Eli Lilly$4K

What the payments were for

  • Consulting fees$348,58988%
  • Speaking & faculty fees$45,00011%
  • Food & beverage$3,7081%
  • Education$700%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Incyte Corporation253$500,358
Icad, Inc23$256,514
Bavarian Nordic A/s62$144,663
Boehringer Ingelheim2$136,895
Blue Earth Diagnostics18$122,310
Partner Therapeutics, Inc.7$86,060
Novocure Inc.17$56,458
Sanofi US Services Inc.6$51,069
Bristol Myers Squibb3$46,932
Jubilant Therapeutics Inc3$45,000
Novocure GmbH8$43,096
Amgen4$39,050
Sunovion Pharmaceuticals Inc.12$22,028
Bayer7$5,900
Boehringer Ingelheim Pharma GmbH & Co.kg1$3,493
Kadmon Corporation LLC1$2,987
AstraZeneca(2 entities)11$2,417
EMD Serono, Inc.2$1,622
Geistlich Pharma, North America, Inc.1$1,500
Boehringer Ingelheim International GmbH1$1,491
Verastem, Inc.2$1,236
Caris MPI, Inc.2$1,018
GT Medical Technologies, Inc3$224
Carl Zeiss Meditec USA, Inc.2$210
Axsome Therapeutics, Inc.1$144
Karyopharm Therapeutics Inc.2$131
Integra Lifesciences Corporation2$131
Epizyme, Inc.2$129
E.r. Squibb & Sons, L.L.C.5$110
Octapharma USA, Inc.3$107
Beigene USA, Inc.5$95
Pfizer4$89
Array Biopharma Inc4$80
Novartis3$72
CSL Behring2$70
Johnson & Johnson2$70
Lilly USA, LLC3$69
Siemens Medical Solutions USA, Inc.2$63
Eisai Inc.3$61
UCB, Inc.2$52
ADC Therapeutics America, Inc.3$52
Argenx US, Inc.2$48
Foundation Medicine, Inc.1$48
Janssen Research & Development, LLC1$46
Neurelis, Inc.2$45
Mallinckrodt Hospital Products Inc.1$33
Telix Pharmaceuticals1$29
Springworks Therapeutics, Inc.1$29
Biogen1$28
Tersera Therapeutics LLC1$28
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$25
Tempus AI, Inc1$25
Regeneron Healthcare Solutions, Inc.1$24
Amneal Pharmaceuticals LLC1$24
Daiichi Sankyo Inc.1$24
Lundbeck LLC1$23
Blueprint Medicines Corporation1$22
Kyowa Kirin, Inc.1$21
Genentech, Inc.1$21
Monteris Medical Corporation1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,574,713 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$102,561
Medicare patients
135
Services billed
906

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5033$353,327
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5018$180,374
LeukineSargramostim48$169,133
TasignaNilotinib Hcl13$131,154
Levetiracetam23$799
Dexamethasone18$376
Hydrocortisone13$329
Hydroxychloroquine Sulfate11$115
Hydralazine Hcl17$86
Propranolol Hcl17$83

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Partner Therapeutics, Inc.Leukine$86,060$169,13348 claims
NovartisTasigna$72$131,15413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,996 neurology providers in California.

Other neurology in Santa Monica

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →